|
Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types. |
|
|
Consulting or Advisory Role - Boehringer Ingelheim |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Merck; Novartis |
|
|
Consulting or Advisory Role - NanoString Technologies (Inst) |
Research Funding - NanoString Technologies (Inst) |
|
|
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche |